Actively Recruiting
Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their Sensitivity to New Anti-tumor Therapies
Led by Centre Antoine Lacassagne · Updated on 2025-09-29
50
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying tumors from patients who have specific genetic mutations to develop a new cell culture method called spheroids. These spheroids are designed to model how tumors respond to different anticancer treatments, allowing scientists to test various drugs on tumor cells that carry the mutation of interest. Tumor samples are collected during routine biopsies or surgeries as part of the patients' standard care. During the study, patients will have tumor samples taken from their scheduled biopsies or surgeries. These samples will be sent to a research laboratory to create spheroids. Additionally, a blood sample of 38 mL will be collected to analyze potential blood-related toxicities from treatments and to explore links between disease stage and exosome levels. This is an interventional study focused on laboratory research using patient tumor material. Participants will be involved in providing tumor samples from their planned medical procedures and giving a blood sample. Researchers will develop and validate spheroid models to study tumor behavior and response to new therapies. The main measure is to successfully create stable spheroids within one month. Safety and blood analyses will also be performed. The study will continue until July 2030, with ongoing evaluation of the tumor models and potential treatment effects.
CONDITIONS
Brief Title
Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their Sensitivity to New Anti-tumor Therapies.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Patient with at least one mutation deemed of interest by the investigator
- Patient with a malignant tumor at a locally advanced or metastatic stage, scheduled for tissue tumor sampling via surgery, radiology, or endoscopy as part of standard care
- Tumor volume sufficient to provide adequate material for analysis and for transfer to the research laboratory
- INR less than 1.5; Platelets greater than 50,000/µL
- Patient informed of the study and has signed the informed consent form
- Patient affiliated with social security insurance
You will not qualify if you...
- Patient with multiple primary malignant tumors
- Patient with known HIV, Hepatitis C, or Hepatitis B infection
- Patient currently on certain blood-thinning medications without possibility of suspension prior to procedure, including Clopidogrel, Prasugrel, Ticlopidine, low molecular weight heparin, Fondaparinux, Abciximab, Eptifibatide, Tirofiban Hydrochloride Monohydrate, Argatroban, Bivalirudin, or Dabigatran etexilate
- Patient considered vulnerable, including pregnant or breastfeeding women; individuals deprived of liberty by judicial or administrative decision; adults under legal protection or unable to express consent; and individuals hospitalized without consent under specific legal provisions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Occurs once as part of routine patient care
Participants undergo surgery or biopsy as part of their routine care to collect tumor samples for research.
1 visit (in-person)
Duration - Occurs once around the time of tumor sampling
A blood sample of 38 mL is taken from participants for analysis related to hematological toxicities and disease study.
1 visit (in-person)
Duration - Up to 1 month
Collected tumor samples and blood are analyzed in the laboratory to develop preclinical models and test their sensitivity to new anti-tumor therapies.
Trial Site Locations
Total: 1 location
1
Centre Antoine Lacassagne
Nice, France, 06189
Actively Recruiting
Research Team
S
Study coordinator
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here